HOME >> MEDICINE >> NEWS
NOVANTRONE application for multiple sclerosis granted priority review by FDA

FDA review of NOVANTRONE data to be completed within six months

SEATTLE-Immunex Corporation (NASDAQ:IMNX) announced today that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the new drug application (NDA) for NOVANTRONER (mitoxantrone for injection concentrate), indicating that the FDA will act on the application within six months of its date of submission. Immunex filed for expanded labeling for NOVANTRONE for the treatment of patients with secondary progressive multiple sclerosis (MS) on June 7, 1999.

"This is an important milestone in the development of NOVANTRONE as a potential treatment for people with secondary progressive MS," said Peggy V. Phillips, senior vice president, pharmaceutical development for Immunex. "We will continue to work closely with the FDA over the next six months as they evaluate these data."

The results of the pivotal NOVANTRONE Phase III study showed that NOVANTRONE had a statistically significant impact on reduction of relapse rate and delay in disability progression in patients with secondary progressive MS. Additional follow-up data presented at a recent international conference showed that one year after treatment was stopped, patients treated with NOVANTRONE continued to experience a reduction in their number of attacks, and a delay in their disability progression.

In the study, treatment with NOVANTRONE resulted in generally manageable side effects that were primarily mild to moderate. During the two-year trial, the most frequent side effects reported by patients treated in the 12 mg/m2 arm were nausea, alopecia (hair loss), upper respiratory tract infection, urinary tract infection, menstrual disorder, and transient neutropenia (a reduced number of white blood cells).

Multiple sclerosis is a chronic, debilitating disease of the central nervous system that, in its various stages, afflicts as many as 350,000 people in the Unit
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
19-Jul-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Considerable reductions in radiation exposure possible with 16-MDCT scanner on body applications
3. AstraZeneca submits regulatory application in Europe for use of Atacand(R) in heart failure
4. Roche files marketing application for Avastin with European health authorities
5. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Research suggests possible blood test for multiple sclerosis
8. Mayo Clinic researchers announce promising next generation treatments for multiple myeloma
9. Good fats decrease multiple heart disease risk factors
10. Swallowing multiple magnets poses danger to children
11. Sleep disorders often indicate multiple health conditions

Post Your Comments:
(Date:8/27/2014)... Spring, Md. (PRWEB) August 27, 2014 ... (CHEST) recently released guidelines for the management and ... Pharmacological Therapy for Pulmonary Arterial Hypertension in Adults: ... are free to view for clinicians, and provide ... PAH. , The Pulmonary Hypertension Association ...
(Date:8/27/2014)... Neward, NJ (PRWEB) August 27, 2014 ... top-10 finish at The Ridgewood County Club during The ... leader board in each of the tournament’s four rounds, ... through the Horizon Blue Cross Blue Shield of New ... BCBSNJ challenged Hoffmann, a Wyckoff native playing before family ...
(Date:8/27/2014)... hormone therapy has spawned a prevalent but preventable side ... flashes, according to a study by a Yale School ... study published in the Aug. 27 online issue of ... moderate to severe hot flashes also called vasomotor ... Women with VMS experience more than feeling hot; other ...
(Date:8/27/2014)... 2014 (HealthDay News) -- Young adults who struggled with ... their brain, researchers are reporting. The findings might ... ways to predict, prevent and treat the illness, according ... The researchers conducted brain scans on 30 volunteers, ages ... years, and a control group of 23 young adults ...
(Date:8/27/2014)... Ticket Down is a dependable source for ... in Santa Clara. Levi’s Stadium is a brand new ... July and will host their first international soccer match on ... two of the best teams that are both coming off ... to continue their successes from the tournament in this international ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Morgan Hoffmann, PGA TOUR Pro & Wyckoff Native, golfs and walks his way to top 10 finish at The Barclays while raising additional $7,500 for charity 2Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Study: Young Adults Who Had Depression Have 'Hyper-Connected' Brain Networks 2Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 2Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 3
(Date:8/27/2014)... -- ISPE , the International Society for Pharmaceutical ... of its Drug Shortages Prevention Plan aimed ... maintain a robust and reliable supply of medications to ... for the industry, was developed by ISPE and its ... industry can best prevent drug shortages from occurring by ...
(Date:8/27/2014)... , Aug. 27, 2014  Hill-Rom Holdings, Inc. ... to a management presentation at the Morgan Stanley Global ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP ... available one hour after conclusion of the live event ...
(Date:8/27/2014)... Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: ... pharmaceutical company with the largest cardio-cerebral vascular ("CCV") ... prescription drug market, today announced the unaudited consolidated ... the "Group") for the six months ended 30 ... the Six months ended 30 JuneKey Income Statement ...
Breaking Medicine Technology:ISPE Releases First Look at its Plan to Prevent Drug Shortages 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 3ISPE Releases First Look at its Plan to Prevent Drug Shortages 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
Cached News: